Stay informed with all the latest news and developments at Interlaw and our strategic partners. Read all about our recent cross-border mandates, partner hires, office openings, pro bono and community activities, award wins and other achievements. For all media and press enquiries please email Imogen Lee, Interlaw's International Director of Marketing and Communications.
Interlaw Singapore Firm Completes Three High-Profile Private Equity Deals
CNPLaw LLP, Interlaw's strategic partner in Singapore, ended 2019 and started 2020 strong with the completion of three private equity deals within the food distribution, pharmaceutical and biotechnology industries.
Leading the team was CNP Partner, Mr Ken Chia, assisted by Ms Hazel Ho (Senior Associate) and Mr Muhammad Parasuram (Associate). Managing Partner, Ms Lisa Theng was also involved in one of the transactions listed below – CNP acted for a Singapore biotechnology company in its series B funding of S$15 million from US and Japanese venture capital firms.
Commenting on the transactions is Mr Chia said: “We are pleased to service such clients and support their business goals with their global counterparts. The successful completion of these transactions showcases the breadth of our experience across difference industries in the private equity / venture capital realm.”
The three private equity deals completed were:
- Acted for one of Japan’s leading fresh produce distributors in its investment of over S$30 million in a Singapore company. On 29 November 2019, CNP finalised a transaction for one of Japan’s leading fresh food distributors in its investment of over S$30 million in equity and exchangeable debt in a Singapore fresh fruit wholesale trader. This transaction marks a significant milestone for the client’s entry into the Singapore market. Upon the completion of the transaction, the client commended the CNP team for their “quick response”.
- Acted for a Hong Kong listed pharmaceutical company in its investment of S$2 million in a Singapore biotechnology company. On 5 December 2019, CNP assisted a Hong Kong listed pharmaceutical company to close its investment of S$2 million in a Singapore biotechnology company. The investment was made by the client’s investment arm via the purchase of convertible notes. The investment contributes towards the advancement of diabetes cell therapy research in Singapore which is currently undertaken by the Singapore biotechnology company.
- Acted for a Singapore biotechnology company in its series B funding of S$15 million from US and Japanese venture capital firms. On 2 January 2020, CNP assisted a Singapore biotechnology company involved in cancer research to raise S$15 million from US and Japanese venture capital firms. This financing round represents the client’s series B funding and strategically positions the client for future market entry into the US.